Gamma neuromodulation improves episodic memory and its associated network in amnestic mild cognitive impairment: a pilot study

Jones, Kevin T.; Gallen, Courtney L.; Ostrand, Avery E.; Rojas, Julio C.; Wais, Peter E.; Rini, James; Chan, Brandon; Lago, Argentina Lario; Boxer, Adam L.; Zhao, Min; Gazzaley, Adam; Zanto, Theodore P.

doi:10.1016/j.neurobiolaging.2023.04.005

Cited by 7 publications

(3 citation statements)

References 157 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More specifically, Kim and colleagues demonstrated that a single 30 min session of 40 Hz TACS stimulation at F3 or F4 (i.e., bilateral DLPFC) improved cognitive control (as measured by Stroop performance) and trail making (a test of executive function with emphasis on attention, processing speed and flexibility) in participants with MCI [ 75 ]. Administering daily sessions of frontal gamma TACS weekly, over 2–4 weeks, was further associated with increased bilateral hippocampal perfusion and bilateral temporal gamma activity [ 77 ]; and, simultaneous administration with a memory challenge for 8 sessions over 4 weeks was associated with improved WM and verbal fluency [ 81 ]. In addition to frontal areas, gamma TACS stimulation at Pz (e.g., precuneus) and of the angular gyrus, whether a single session or daily sessions over weeks, have also been associated with improved WM and verbal fluency [ 82 ], including in comparison to sham stimulation [ 74 , 78 ].…”

Section: Recent Studies Testing Gamma Neuromodulation As Treatment Fo...mentioning

confidence: 99%

A Focused Review of Gamma Neuromodulation as a Therapeutic Target in Alzheimer’s Spectrum Disorders

2024

J Psychiatry Brain Sci

View full text Add to dashboard Cite

The aging population of the world is increasing at an unprecedented rate which is expected to lead to a corresponding unparalleled increase in age related diseases. Of particular concern are the large number of older adults expected to develop Alzheimer’s disease (AD), which will require extraordinary local, national and worldwide healthcare resources. In this context, innovative interventions are needed urgently to delay AD onset and thereby give our healthcare systems time to prepare and provide meaningful care to our aging populations. This focused review discusses the crucial role of frontal gamma oscillations as a therapeutic target to delay or ameliorate cognitive decline in AD. Frontal gamma oscillations, including from prefrontal cortical areas, serve as a biomarker for working memory and other cognitive functions, and their impairment is observed before clinical symptoms manifest. This review evaluates evidence from animal models and human subjects to highlight the correlation between gamma wave abnormalities and cognitive deterioration. Furthermore, the review summarizes 11 clinical studies using neuromodulation techniques designed to stimulate gamma oscillations in mild cognitive impairment (MCI) and AD patients, including transcranial electrical stimulation, transcranial magnetic stimulation, and rhythmic sensory stimulation. These interventions have shown promise in mitigating early-stage cognitive decline, as evidenced by improved performance on memory tests, increased gamma oscillatory responses, and some have even shown reduced brain atrophy. These early studies suggest that treatments that strengthen frontal gamma oscillatory responses through neuromodulation are a promising approach to delay cognitive decline, that may serve as an adjunct to other therapies or as a standalone treatment in some populations.

show abstract

Section: Recent Studies Testing Gamma Neuromodulation As Treatment Fo...mentioning

confidence: 99%

A Focused Review of Gamma Neuromodulation as a Therapeutic Target in Alzheimer’s Spectrum Disorders

2024

J Psychiatry Brain Sci

View full text Add to dashboard Cite

show abstract

“…Another ongoing study focuses on amnestic MCI patients using tACS combined with mnemonic tasks to engage episodic memory [ 137 ] (clinical trial NCT04646499). It also evaluates plasma AD biomarkers and neuroplastic changes through rs-fMRI connectivity and neuronal excitation/inhibition (E/I) balance.…”

Section: Current Knowledge Of Gamma Tacs For the Treatment Of Admentioning

confidence: 99%

Transcranial alternating current stimulation (tACS) at gamma frequency: an up-and-coming tool to modify the progression of Alzheimer’s Disease

De Paolis,

Paoletti,

Zaccone

et al. 2024

Transl Neurodegener

View full text Add to dashboard Cite

The last decades have witnessed huge efforts devoted to deciphering the pathological mechanisms underlying Alzheimer’s Disease (AD) and to testing new drugs, with the recent FDA approval of two anti-amyloid monoclonal antibodies for AD treatment. Beyond these drug-based experimentations, a number of pre-clinical and clinical trials are exploring the benefits of alternative treatments, such as non-invasive stimulation techniques on AD neuropathology and symptoms. Among the different non-invasive brain stimulation approaches, transcranial alternating current stimulation (tACS) is gaining particular attention due to its ability to externally control gamma oscillations. Here, we outline the current knowledge concerning the clinical efficacy, safety, ease-of-use and cost-effectiveness of tACS on early and advanced AD, applied specifically at 40 Hz frequency, and also summarise pre-clinical results on validated models of AD and ongoing patient-centred trials.

show abstract

“…More importantly, about two-thirds of patients diagnosed with moderate to severe disease missed the optimal intervention time. Amnestic mild cognitive impairment (aMCI) is recognized as an early stage of AD ( 2 , 3 ). Therefore, early diagnosis, early intervention, and delay in disease progression are the main research directions for managing AD, which is of great significance for improving the quality of life of patients and reducing the burden on the family and society.…”

Section: Introductionmentioning

confidence: 99%

Functional brain activity in patients with amnestic mild cognitive impairment: an rs-fMRI study

Yue,

Han,

Liu

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

BackgroundAmnestic mild cognitive impairment (aMCI) is an early stage of Alzheimer’s disease (AD). Regional homogeneity (ReHo) and amplitude of low-frequency fluctuation (ALFF) are employed to explore spontaneous brain function in patients with aMCI. This study applied ALFF and ReHo indicators to analyze the neural mechanism of aMCI by resting-state functional magnetic resonance imaging (rs-fMRI).MethodsTwenty-six patients with aMCI were included and assigned to the aMCI group. The other 26 healthy subjects were included as a healthy control (HC) group. Rs-fMRI was performed for all participants in both groups. Between-group comparisons of demographic data and neuropsychological scores were analyzed using SPSS 25.0. Functional imaging data were analyzed using DPARSF and SPM12 software based on MATLAB 2017a. Gender, age, and years of education were used as covariates to obtain ALFF and ReHo indices.ResultsCompared with HC group, ALFF decreased in the left fusiform gyrus, left superior temporal gyrus, and increased in the left cerebellum 8, left inferior temporal gyrus, left superior frontal gyrus (BA11), and right inferior temporal gyrus (BA20) in the aMCI group (p < 0.05, FWE correction). In addition, ReHo decreased in the right middle temporal gyrus and right anterior cuneiform lobe, while it increased in the left middle temporal gyrus, left inferior temporal gyrus, cerebellar vermis, right parahippocampal gyrus, left caudate nucleus, right thalamus, and left superior frontal gyrus (BA6) (p < 0.05, FWE correction). In the aMCI group, the ALFF of the left superior frontal gyrus was negatively correlated with Montreal Cognitive Assessment (MoCA) score (r = −0.437, p = 0.026), and the ALFF of the left superior temporal gyrus was positively correlated with the MoCA score (r = 0.550, p = 0.004). The ReHo of the right hippocampus was negatively correlated with the Mini-Mental State Examination (MMSE) score (r = −0.434, p = 0.027), and the ReHo of the right middle temporal gyrus was positively correlated with MMSE score (r = 0.392, p = 0.048).ConclusionFunctional changes in multiple brain regions rather than in a single brain region have been observed in patients with aMCI. The abnormal activity of multiple specific brain regions may be a manifestation of impaired central function in patients with aMCI.

show abstract

Gamma neuromodulation improves episodic memory and its associated network in amnestic mild cognitive impairment: a pilot study

Cited by 7 publications

References 157 publications

A Focused Review of Gamma Neuromodulation as a Therapeutic Target in Alzheimer’s Spectrum Disorders

A Focused Review of Gamma Neuromodulation as a Therapeutic Target in Alzheimer’s Spectrum Disorders

Transcranial alternating current stimulation (tACS) at gamma frequency: an up-and-coming tool to modify the progression of Alzheimer’s Disease

Functional brain activity in patients with amnestic mild cognitive impairment: an rs-fMRI study

Contact Info

Product

Resources

About